Novo CEO on US obesity drug demand: "It was the perfect storm"

At the start of 2022, Novo Nordisk expects to be able to meet the demand for its obesity drug Wegovy in the US. The patient interest was so high, it surprised the CEO.

Photo: Stine Bidstrup/ERH

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, does not think anyone can be blamed for the production problems that have affected the company as a result of the launch of Wegovy in the US. His reasoning is that nobody could have predicted the enormously high demand for the drug.

"We launched Wegovy based on our experiences with Saxenda. That is a best-selling product, but the sales haven't blown us away," he says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs